Effectiveness of growth hormone therapy in children with Noonan syndrome
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Recombinant human growth hormone (rhGH) has been used to improve growth in children with Noonan syndrome (NS). This study aimed to investigate the efficacy of rhGH therapy in Korean children with NS. Methods: Seventeen prepubertal children (10 boys, 7 girls) with NS who received rhGH therapy for at least 3 years between 2008 and 2017 were included. To compare the response, age- and sex-matched children with GH deficiency (GHD; n=31) were included. Height and growth velocity before and during treatment were analyzed. Results: The mean age of NS patients was 6.34±2.32 years. After treatment, the height standard deviation score (SDS) increased from -2.93±0.81 to -1.51±1.00 in patients with NS and from -2.45±0.42 to -1.09±0.47 in patients with GHD. There were no significant differences in growth velocity or change in height SDS between patients with NS and GHD. Growth velocity in the first year of treatment was higher in patients with PTPN11 mutations than those without PTPN11 mutations, but the change in height SDS was not significantly different between those 2 groups. Conclusion: rhGH therapy can increase linear growth in prepubertal children with NS. The growth response between patients with NS and patients with GHD was not significantly different. Furthermore, we observed that lower doses of growth hormone have a similar effect on height compared to previous studies in patients with NS. Our study indicates that rhGH treatment is useful for growth promotion.
Abstract
Purpose: Recombinant human growth hormone (rhGH) has been used to improve growth in children with Noonan syndrome (NS). This study aimed to investigate the efficacy of rhGH therapy in Korean children with NS. Methods: Seventeen prepubertal children (10 boys, 7 girls) with NS who received rhGH therapy for at least 3 years between 2008 and 2017 were included. To compare the response, age- and sex-matched children with GH deficiency (GHD; n=31) were included. Height and growth velocity before and during treatment were analyzed. Results: The mean age of NS patients was 6.34±2.32 years. After treatment, the height standard deviation score (SDS) increased from -2.93±0.81 to -1.51±1.00 in patients with NS and from -2.45±0.42 to -1.09±0.47 in patients with GHD. There were no significant differences in growth velocity or change in height SDS between patients with NS and GHD. Growth velocity in the first year of treatment was higher in patients with PTPN11 mutations than those without PTPN11 mutations, but the change in height SDS was not significantly different between those 2 groups. Conclusion: rhGH therapy can increase linear growth in prepubertal children with NS. The growth response between patients with NS and patients with GHD was not significantly different. Furthermore, we observed that lower doses of growth hormone have a similar effect on height compared to previous studies in patients with NS. Our study indicates that rhGH treatment is useful for growth promotion.
참고문헌 (25)
- Roberts AE, "Noonan syndrome", Lancet, 381, pp.333~342 (2013)
- Binder G, "Noonan syndrome, the Ras-MAPK signalling pathway and short stature", Horm Res, 71(Suppl 2), pp.64~70 (2009)
- Noordam K, "Expanding the genetic spectrum of Noonan syndrome", Horm Res, 68(Suppl 5), pp.24~27 (2007)
- Romano AA, "Noonan syndrome : clinical features, diagnosis, and management guidelines", Pediatrics, 126, pp.746~759 (2010)
- Padidela R, "Abnormal growth in noonan syndrome : genetic and endocrine features and optimal treatment", Horm Res, 70, pp.129~136 (2008)
- Yart A, "Noonan syndrome : an update on growth and development", Curr Opin Endocrinol Diabetes Obes, 25, pp.67~73 (2018)
- van der Burgt I, "Noonan syndrome", Orphanet J Rare Dis, 2, pp.4~ (2007)
- Hyun SE, "Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3in Korean children and adolescents", Clin Biochem, 45, pp.16~21 (2012)
- 김재현, "The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects", Clinical and Experimental Pediatrics, 61(5), pp.135~149 (2018), 대한소아청소년과학회
- Greulich WW, "Radiologic atlas of skeletal development of the hand and wrist", pp.53~ (1959), Stanford University Press
- Wheeler MD, "Physical changes of puberty", Endocrinol Metab Clin North Am, 20, pp.1~14 (1991)
- Kyo Jin Jo, "Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome", Clinical and Experimental Pediatrics, 62(7), pp.274~280 (2019), 대한소아청소년과학회[DOI]
- Insook Jeong, "Long-term efficacy of recombinant human growth hormone therapy in short-statured patients with Noonan syndrome", Annals of Pediatric Endocrinology & Metabolism, 21(1), pp.26~30 (2016), 대한소아내분비학회
- Zavras N, "Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency", Ital J Pediatr, 41, pp.71~ (2015)
- Choi JH, "Response to growth hormone therapy in children with Noonan syndrome : correlation with or without PTPN11gene mutation", Horm Res Paediatr, 77, pp.388~393 (2012)
- Romano AA, "Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone", J Clin Endocrinol Metab, 94, pp.2338~2344 (2009)
- Osio D, "Improved final height with long-term growth hormone treatment in Noonan syndrome", Acta Paediatr, 94, pp.1232~1237 (2005)
- De Schepper J, "Growth hormone therapy in prepubertal children with Noonan syndrome : first year growth response and comparison with Turner syndrome", Acta Paediatr, 86, pp.943~946 (1997)
- Giacomozzi C, "The impact of growth hormone therapy on adult height in noonan syndrome : a systematic review", Horm Res Paediatr, 83, pp.167~176 (2015)
- Noonan JA, "The efficacy and safety of growth hormone therapy in children with noonan syndrome : a review of the evidence", Horm Res Paediatr, 83, pp.157~166 (2015)
- Binder G, "PTPN11mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome", J Clin Endocrinol Metab, 90, pp.5377~5381 (2005)
- Malaquias AC, "Impact of growth hormone therapy on adult height in patients with PTPN11mutations related to Noonan syndrome", Horm Res Paediatr, 91, pp.252~261 (2019)
- Noordam C, "Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, nonreceptor-type 11", Eur J Endocrinol, 159, pp.203~208 (2008)
- 이슬, "Noonan 증후군과 성장호르몬결핍증 환아에서 성장호르몬 치료 효과", Annals of Pediatric Endocrinology & Metabolism, 16(2), pp.100~105 (2011), 대한소아내분비학회
- Ozono K, "Efficacy and safety of two doses of Norditropin((R))(somatropin)in short stature due to Noonan syndrome : a 2-year randomized, double-blind, multicenter trial in Japanese patients", Endocr J, 65, pp.159~174 (2018)